Form 4: Aurinia Exec's Stock Holdings Update

Aurinia Pharmaceuticals' EVP, General Counsel Stephen P. Robertson reported an acquisition of shares from a performance award and a disposition for tax withholding, adjusting his beneficial ownership.

Summary

• Stephen P. Robertson, EVP, General Counsel of Aurinia Pharmaceuticals Inc. (AUPH), reported changes in his beneficial ownership of common stock.
• On January 2, 2026, Robertson acquired 48,558 shares of common stock as part of a performance award.
• Concurrently, 40,385 shares were disposed of on January 2, 2026, to satisfy tax withholding obligations related to the vesting of performance awards, at a price of $15.95 per share.
• Following these transactions, Robertson beneficially owns 517,934 shares of Aurinia Pharmaceuticals common stock.
• The acquired performance award shares are scheduled to vest in two equal annual installments on December 31, 2025, and December 31, 2026.
• The reported beneficial ownership also includes 531 common shares acquired on May 30, 2025, and 354 common shares acquired on November 28, 2025, through the Issuer's 2021 Employee Share Purchase Plan.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving the vesting of performance awards and subsequent tax withholding. While there's a disposition of shares, it's for tax purposes, and the underlying acquisition of shares from a performance award is a positive indicator of executive performance and retention. The overall impact is neutral to slightly positive, reflecting standard compensation practices.

Positives

• Stephen P. Robertson acquired 48,558 shares of common stock from a performance award, indicating achievement of performance metrics.
• The performance award shares will vest in two equal annual installments on December 31, 2025, and December 31, 2026, providing future equity incentives.
• The reporting person also acquired additional shares through the company's Employee Share Purchase Plan (531 shares on May 30, 2025, and 354 shares on November 28, 2025), demonstrating continued investment in the company.

Negatives

• 40,385 shares were disposed of to cover tax withholding obligations, which is a reduction in direct beneficial ownership.

Future Outlook

The performance award shares acquired by Stephen P. Robertson are scheduled to vest in two equal annual installments on December 31, 2025, and December 31, 2026, indicating future equity compensation events.

Industry Context

This Form 4 filing details routine insider transactions related to executive compensation and share ownership. It does not provide information directly related to broader industry trends or competitive landscape, focusing solely on an individual executive's equity movements within Aurinia Pharmaceuticals.

Comparison to Industry Standards

• This filing is a standard Form 4 reporting insider transactions, specifically the vesting of performance awards and subsequent tax withholding.
• Such transactions are common practice for executive compensation across publicly traded companies and align with typical corporate governance structures for equity incentives.
• No specific comparable companies, projects, or results are detailed within this transactional filing.

Stakeholder Impact

• Shareholders: Minor impact as it reflects routine executive compensation and share ownership adjustments. The executive's continued beneficial ownership of a significant number of shares (517,934) aligns executive interests with shareholder value.
• Employees: The mention of an Employee Share Purchase Plan (ESPP) indicates a broader program for employee equity participation.

Next Steps

• First equal annual installment of performance award shares to vest on December 31, 2025.
• Second equal annual installment of performance award shares to vest on December 31, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions for Stephen P. Robertson, EVP, General Counsel of Aurinia Pharmaceuticals. It involves the vesting of a performance award and a subsequent disposition of shares to cover tax obligations. Such transactions are standard for executive compensation and do not typically signal a significant change in the company's fundamental outlook or warrant a strong buy or sell recommendation. The executive's continued substantial beneficial ownership suggests alignment with long-term company performance.

Keywords

Aurinia Pharmaceuticals, AUPH, Insider Transaction, Form 4, Executive Compensation, Stock Ownership, Performance Award, Tax Withholding, Beneficial Ownership